Ozempic alternatives range from FDA-approved options to investigational compounds with distinct efficacy profiles. Semaglutide (Wegovy) produces average 14.9% weight loss; tirzepatide (Zepbound) achieves 22.5% in SURMOUNT-1; and the investigational retatrutide reached 28.7% — the highest of any obesity drug tested to date. This comparison covers efficacy, cost, availability, and side effects across all categories.
The Problem
Ozempic and Wegovy changed weight loss forever — but they're not perfect for everyone. Here's why millions of people are searching for alternatives.
$1,000–$1,350/month without insurance. Many plans don't cover weight loss medications, and prior authorization denials are common.
Nausea, vomiting, and GI distress affect 15–25% of users. Some people can't tolerate semaglutide but respond well to other GLP-1 drugs.
Demand has consistently outstripped supply since 2022. Certain doses remain intermittently unavailable, disrupting treatment continuity.
Newer drugs like tirzepatide achieve ~50% more weight loss than semaglutide. Next-gen compounds in trials show even greater efficacy.
Available Now
These drugs are currently available by prescription. Tirzepatide is the standout — achieving significantly more weight loss than semaglutide through its dual-agonist mechanism.
Coming Soon
The next generation of weight loss drugs in clinical trials. These aren't available yet but represent where the field is heading — and they may make today's options obsolete.
The most effective obesity drug ever tested. Retatrutide is a triple agonist targeting GIP, GLP-1, and glucagon receptors simultaneously. The glucagon component drives direct fat burning and energy expenditure — a mechanism no approved drug uses. Phase 3 TRIUMPH-4 data showed 28.7% average weight loss.
A dual GLP-1/glucagon agonist (different dual combo than tirzepatide). Phase 2 data showed ~19% weight loss at 46 weeks. Also being studied for MASH/NAFLD (fatty liver disease), where it showed significant liver fat reduction — potentially a two-for-one drug.
A non-peptide oral GLP-1 agonist — meaning it's a pill, not an injection, and doesn't need to be taken on an empty stomach like Rybelsus. Phase 2 showed ~14.7% weight loss at 36 weeks. Could be a game-changer for the injection-averse.
Novo Nordisk's answer to the oral GLP-1 challenge. Amycretin is a dual amylin/GLP-1 agonist in pill form. Early Phase 1/2 data showed ~13.1% weight loss at just 12 weeks — suggesting a potentially steep weight loss curve. Still early stage.
The Budget Option
Same active ingredient as Ozempic, prescribed by a physician, made by compounding pharmacies — at a fraction of the brand-name cost.
When the FDA classifies a drug as being in shortage, compounding pharmacies are legally permitted to produce copies of that drug. Semaglutide has been classified as in shortage since 2022 due to unprecedented demand.
Compounded semaglutide contains the same active ingredient as Ozempic and Wegovy but is produced by compounding pharmacies rather than Novo Nordisk. It requires a physician prescription and is available through telehealth platforms and prescribing physicians.
In early 2025, the FDA reclassified semaglutide under Category 1 of its shortage framework. This means compounding pharmacies can continue producing semaglutide under specific conditions, but the regulatory landscape is evolving. Patients should verify current availability with their prescriber.
Compounded semaglutide is not an FDA-approved product. Quality varies between pharmacies. Look for pharmacies that provide certificates of analysis (COA) and third-party testing. The regulatory status may change — always verify with your prescriber.
Compounded semaglutide works the same way as Ozempic because it is the same molecule. The difference is manufacturing oversight. Brand-name products go through FDA manufacturing inspections; compounded products are regulated by state pharmacy boards.
No Prescription Required
Supplements, lifestyle changes, and non-prescription approaches. We'll be honest: none of these come close to prescription GLP-1 drugs, but they have their place.
Side-by-Side
All alternatives in one view. Scroll horizontally on mobile. Sort by what matters most to you — efficacy, cost, or availability.
| Drug / Option | Mechanism | Efficacy | Monthly Cost | Route | Availability | Key Side Effects |
|---|---|---|---|---|---|---|
| Tirzepatide Zepbound |
Dual GIP + GLP-1 | 22.5% | $1,060 | Weekly injection | Available now | Nausea, diarrhea, constipation |
| Semaglutide Wegovy/Ozempic |
GLP-1 only | 14.9% | $1,000–1,350 | Weekly injection | Available now | Nausea, vomiting, diarrhea |
| Liraglutide Saxenda |
GLP-1 only (older) | 8.0% | $1,350 | Daily injection | Available now | Nausea, headache, hypoglycemia |
| Rybelsus Oral semaglutide |
GLP-1 (oral) | 4.4% | $936 | Daily pill | Approved (T2D) | Nausea, abdominal pain |
| Retatrutide Triple agonist |
GIP + GLP-1 + GCG | 28.7% | TBD | Weekly injection | Phase 3 (2026–27) | Nausea, diarrhea, vomiting |
| Survodutide | GLP-1 + Glucagon | ~19% | TBD | Weekly injection | Phase 3 | GI effects, liver enzyme changes |
| Orforglipron | Non-peptide GLP-1 (oral) | 14.7% | TBD | Daily pill | Phase 3 | Nausea, vomiting, diarrhea |
| Amycretin | Amylin + GLP-1 (oral) | 13.1%* | TBD | Daily pill | Phase 2 | GI effects (early data) |
| Compounded Semaglutide | GLP-1 only | ~14.9% | $150–500 | Weekly injection | Physician Rx | Same as brand semaglutide |
| Berberine | AMPK activator | 2–5 lbs | $15–30 | Oral supplement | OTC | GI discomfort, drug interactions |
| Diet + Exercise | Lifestyle | 5–10% | Free | N/A | Always available | Requires sustained effort |
* Amycretin 13.1% was at 12 weeks only; longer-term data pending. All other figures are at study endpoint (36–72 weeks).
Safety Profile
Most GLP-1 drugs share similar side effects because they work through related pathways. Rates shown are typical across the drug class at therapeutic doses.
Starting at the lowest dose and gradually increasing over 4–16 weeks dramatically reduces GI side effects. Most nausea and vomiting occurs during the first few weeks of each dose increase and improves with time.
All GLP-1 drugs carry rare risks of pancreatitis, gallbladder events, and potential thyroid C-cell tumors (seen in rodents, unclear in humans). These are listed as boxed warnings. Always discuss personal risk factors with your physician.
GLP-1 drugs cause weight loss from both fat and lean mass. Resistance training (2–3x/week) and adequate protein intake (1g/lb lean mass) can significantly preserve muscle during treatment.
Bottom Line
What matters most for different situations.
Dive Deeper
Research breakdowns, calculators, and comparison tools for every GLP-1 drug mentioned above.
Recommended
Track your progress and support your protocol with these essentials.
Affiliate links help support MeetPeptide at no extra cost to you.
Dosing schedules, interaction warnings, and cycle protocols for 50+ compounds — all in one place.
⚕️ Medical Disclaimer: This page is for educational and informational purposes only. It is not medical advice and should not be used as a substitute for professional medical consultation. All medications discussed carry risks and require physician oversight. Never start, stop, or change medications without consulting a qualified healthcare provider. Weight loss results vary by individual. Data sourced from published peer-reviewed clinical trials (STEP, SURMOUNT, TRIUMPH, SCALE, PIONEER). Always verify current drug availability and pricing with your pharmacy or prescriber.
MeetPeptide · Research Library · © 2026